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Abstract
Background: Albuminuria has been considered an important diagnostic marker of decreasing renal function, but lately 
albuminuria has also been linked to cardiovascular and peripheral vascular disease. Many studies have analyzed the 
association between micro- or macroalbuminuria and the increased risk of cardiovascular disease, but only few examined 
the association between normoalbuminuria and cardiovascular disease. To analyze the association between the degree of 
normoalbuminuria and the occurrence of left ventricular diastolic dysfunction in hypertensive patients.
Method: This is cross-sectional analysis in hypertensive patients. Normoalbuminuric subjects are divided into three tertiles 
based on the cutoff of Urine-Albumin-Creatinine Ratio (UACR). To evaluate left ventricular function, all subjects undergo 
echocardiography examination. Left ventricular diastolic dysfunction is positive if more than fifty percent of positive findings 
are present from the fourth parameters stated in the 2016 American Society of Echocardiography criterias.
Results: No significant difference in the occurrence of LVDD was found between the two groups according to age, sex, 
smoking, dyslipidemia, physical activity, BMI, hypertension therapy and HbA1c, but a significant difference was seen in the 
UACR tertile of the two group. This study showed that upper-limit normoalbuminuria (third tertile) was associated with 
the occurrence of LVDD (OR 15.57, 95% CI: 2.88-84.25).
Conclusion: This study showed that normoalbuminuria in hypertensive population is associated with left ventricular 
diastolic dysfunction.
(Indonesian J Cardiol. 2019;40:233-242)
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Introduction
Prevalence of hypertension accounts for 30% - 40% of the general population, and it increases with age.1 Data which is taken from “Riset Kesehatan Dasar” (Riskesdas) Indonesia on 2013, 
the prevalence of hypertension was 25.8%. Provinces 
that have the highest prevalence in Indonesia are Bangka 
Belitung (30,9%), South Borneo (30,8%), East Borneo 
Clinical Research doi: 10.30701/ijc.v40i2.764
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(29,6%) and West Java (29,4%). Hypertension is a risk 
factor of Left Ventricular Distolic Dysfunction (LVDD) 
and being the most common cause of heart failure.3 This 
concept has a similarity with study from Perkiomaki, 
et al, which states that increase of blood pressure both 
systolic and pulse pressure has a relation with diastolic 
dysfunction. The Renin Angiotensin Aldosterone 
System (RAAS) has the main role of the occurrence of 
LVDD and its progression to become heart failure with 
normal systolic function. Nowadays LVDD is predicted 
as the bridging pathophysiology between hypertension 
and heart failure. 3
 Hyperfiltration of glomerulus and endothelial 
dysfunction has been known as the beginning of essential 
hypertension before the raise in blood pressure.4 These 
conditions will cause albuminuria. Albuminuria is an 
increase of the serum albumin (protein) excretion to 
urine. Typically, albuminuria had been an important 
diagnostic finding and representing kidney function, 
but nowadays albuminuria is considered as a diagnostic 
finding for cardiovascular and peripheral vascular 
disease that links the process between cardiovascular 
and kidney. A lot of research has been studying the 
association between microalbuminuria (30-300 mg/g) 
or macroalbuminuria (≥300 mg/g) and increasing risk of 
cardiovascular disease, but there were only few researches 
about the association between normoalbuminuria with 
cardiovascular disease. Micro or macroalbuminuria 
is more likely caused by glomerular permeability 
dysfunction while normoalbuminuria (<30 mg/g) is 
caused by retrieval pathway dysfunction, where there 
is only small amount of filtered albumin that does not 
pass through the retrieval pathway and go through the 
process of lysosomal degradation and excreted in urine 
as a small peptide fragment. This degradation pathway 
is sensitive to metabolic factor that responsible for 
hypertrophy and fibrosis process, especially angiotensin 
II (AII) and transforming growth factor - β ( TGF-β), 
which production is stimulated by hyperglycemia and 
hypertension.5. It is important to note that increase 
of RAAS and TGF are involved in dysfunction of the 
heart and also being a manifestation of hypertrophic 
and fibrotic process in the heart which causes structural 
changes such as LVDD and associated with increase 
of significant cardiovascular risk. Therefore, by 
understanding mechanism of albuminuria might give 
us knowledge about the underlying molecular process 
Table 1 Subject Characteristic (N= 62) 
Variables Value
Age 52,68 ± 12,74
Gender
  Male
  Female
22 (35,5%)
40 (64,5%)
Smoking
 No
 Yes
47 (75,8%)
15 (24,2%)
Dyslipidemia
 No
 Yes
51 (82,3%)
11 (17,7%)
Physical Activity
 No
 Yes
38 (61,3 %)
24 (38,7%)
Antihypertensive Therapy
 No
 Yes
38 ( 61.3 %)
24 ( 38,7% )
    Not knowing the name of the drug
    Captopril
    Amlodipin
19 (79.16%)
4 (16.66%)
1 (4.16%)
LVDD
 Negative
 Positive
22 (35,5%)
40 (64,5%)
Physical Examination
 Body weight (kg)
 Body height (cm)
 Body Mass Index
59,85 ± 11,81
151,13 ± 10,07
26,26 ± 2,98
Blood Pressure (mmHg)
 Systolic pressure in first examination
 Systolic pressure in second examination  (after 
2 weeks)
 Diastolic pressure in first examination
 Diastolic pressure in second examination (after 
2 weeks)
162,05 ± 17,150
159,15 ± 18,45
97,29± 7,56
96,50 (90 – 131)
Laboratory Findings
 Urine Albumin Creatinin Ratio /UACR 
(mg/gram)
 HbA1C
10.66 + 7.84
5,38 ± 0,39
Tertile UACR 
 Tertile 1
 Tertile 2
 Tertile 3
11 (17,7%)
17 (27,4%)
34 (54,8%)
*normal numerical data dispersion expressed in mean ± 
standard deviation, if the dispersion is not normal it is 
expressed in median (minimum-maximum)
of the disease.5 
 Most of the researchers agreed that albuminuria 
is associated with morbidity and mortality risk of 
cardiovascular events in general population6, and 
becoming a high risk in patients with diabetes mellitus 
and hypertension7,8. The role of microalbuminuria as 
a marker of glomerular hyperfiltration, endothelial and 
cardiovascular dysfunction and LVDD is explained 
Indonesian J Cardiol ● Vol. 40, Issue 2 ● April - June 2019 235
Indonesian Journal of Cardiology 
in someone with hypertension9, but the role of 
normoalbuminuria as a biomarker of preclinical 
hypertensive disease and LVDD has not been researched 
prospectively.4 
There were only few researches that evaluated the 
association between normoalbuminuria (equal 
or less than 30 mg/g, that the range is below 
microalbuminuria) and left ventricular diastolic 
function. In a research which samples is normotensive 
people with normoalbuminuria, upper border of 
albumin concentration in urine can predict the progress 
of some cardiovascular disease such as hypertension 
and metabolic syndrome 10,11. The same finding can 
be found in a high-risk population (hypertensive 
people) which has a high level of UACR (urine albumin 
creatinine ratio) but still lower than the upper border 
of microalbuminuria significantly associated with 
the increase of LVDD prevalence in CAD patients 
that undergone percutaneous coronary intervention. 
Prevalence of LVDD with normoalbuminuria in CAD 
patients’ population was 29.2%.12 It is shown that 
normoalbuminuria in a high risk population can make 
a stratification of cardiovascular risk.
Methods
The research is  cross-sectional study. Research subject 
is hypertensive patients without heart failure symptoms 
who was examined based on first screening which had 
done by public health service in Bogor during January 
to February 2017.
 Inclusion Criteria was patient with uncontrolled 
hypertension according to The Eighth Joint 
National Committee Guideline. Age ≥ 18 years and 
normoalbuminuria. We rule out subject with micro/
macroalbuminuria, symptoms of heart failure, 
moderate to severe valvular heart disease, arrythmia 
(atrial fibrilation), history of PCI/ CABG, left ejection 
fraction function < 40%, diabetes, obesity, LVH and 
subject with hypertension therapy. Urine analysis and 
echocardiography was done by the staff from Non-
Invasive Diagnostic Division of National Cardiovascular 
of Harapan Kita, Indonesia.
 Classification of normoalbuminuria in this study 
is taken from previous study which classification was 
already tested on coronary disease population21. UACR 
<3.4 mg/g, 3.4 mg/ gram ≤ UACR < 7.4 mg/g and 7.4 
mg/ gram ≤  UACR < 30 mg/g.
 LVDD is a condition that is related to thickening 
and narrowing of ventricular chamber, in which made 
a decrease in one or both ventricular filling, with 
normal systolic function. This definition is based on 
echocardiography, especially mitral inflow velocity 
and TDI, to define either normal diastolic function 
or LVDD. LVDD is considered positive when there is 
more than 50% positive findings from four parameters 
according to the criteria from American Society of 
Echocardiography (ASE) 2016: mean comparison E/e’ 
> 14, septal velocity < 7 cm/second or lateral < 10 cm/
second, tricuspid regurgitation velocity > 2.8 m/second, 
left atrial volume index > 34 mL/m2 23
Results
The number of samples or subjects is one hundred 
twenty six (126) taken from January 2017 to February 
2017. Sixty four (64) samples were excluded due to 
exclusion criteria and eventually left sixty two (62) 
samples to be going on this research as research subjects 
(Figure 5.1).
 
Initial Sample ( n = 126 ) 
Final Sample ( n = 62 ) 
Exclusion Criteria : 
• Micro/macroalbuminuria : 58 
• Heart Failure Symptoms   : 0 
• Valvular Heart Disease      : 1 
• Atrial Fibrillation                : 1 
• History of PCI/CABG          : 0 
• EF < 40 %                              : 1 
• Diabetes Melitus                : 19 
• Obesity       : 43 
• LVH ( based on LV mass index)   : 61 
  
Figure 1 Sampling Methods
 Gender of the subjects is dominantly female 
(64.2%), mean age is 52 years old, with no habit of 
smoking (75.8%), no history of dyslipidemia (82.3%), 
no physical activity (61.3%) and mean albuminuria is 
10.66 + 7.84 mg/gram. Among sixty two patients, forty 
two patients have left ventricular diastolic dysfunction 
(64.5%). Characteristic data is shown on Table 1
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Table 2 Subject Characteristic (N= 62) 
Variables Value
Age 52,68 ± 12,74
Gender
  Male
  Female
22 (35,5%)
40 (64,5%)
Smoking
 No
 Yes
47 (75,8%)
15 (24,2%)
Dyslipidemia
 No
 Yes
51 (82,3%)
11 (17,7%)
Physical Activity
 No
 Yes
38 (61,3 %)
24 (38,7%)
Antihypertensive Therapy
 No
 Yes
38 ( 61.3 %)
24 ( 38,7% )
    Not knowing the name of the drug
    Captopril
    Amlodipin
19 (79.16%)
4 (16.66%)
1 (4.16%)
LVDD
 Negative
 Positive
22 (35,5%)
40 (64,5%)
Physical Examination
 Body weight (kg)
 Body height (cm)
 Body Mass Index
59,85 ± 11,81
151,13 ± 10,07
26,26 ± 2,98
Blood Pressure (mmHg)
 Systolic pressure in first examination
 Systolic pressure in second examination  (after 2 weeks)
 Diastolic pressure in first examination
 Diastolic pressure in second examination (after 2 weeks)
162,05 ± 17,150
159,15 ± 18,45
97,29± 7,56
96,50 (90 – 131)
Laboratory Findings
 Urine Albumin Creatinin Ratio /UACR (mg/gram)
 HbA1C
10.66 + 7.84
5,38 ± 0,39
Tertile UACR 
 Tertile 1
 Tertile 2
 Tertile 3
11 (17,7%)
17 (27,4%)
34 (54,8%)
Echocardiography
LVEF (%)
Right ventricular systolic function / TAPSE (cm)
LV Mass index male (g/m²)
LV Mass index female (g/m²)
LVEDD (mm)
LVESD (mm)
IVSD (mm)
IVSS (mm)
LVPWD (mm)
LVPWS (mm)
Left Atrial Volume Index / LAVI (ml/m²)
Medial e wave velocity (cm/second)
Lateral e wave velocity (cm/second)
Mean E/e’ wave
70.38 + 3.03
2.12 (2 - 2.5)
90,79 ± 14,77
86,18 ± 10,64
44,35 ± 4,77
25,64 ± 4,59
10,64 ± 1,72
15,32 ± 2,07
10,00 (8 – 18)
15,00 (13 – 20)
39,64 + 11,33
7 (3 – 12)
7.5 (4 – 16)
16 (6 – 28)
*normal numerical data dispersion expressed in mean ± standard deviation, if the dispersion is not normal it is expressed in 
median (minimum-maximum)
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Table 3 Relationship between demographic characteristic with LVDD
Variable
LVDD
P value
Yes (N = 40) No (N =22 )
Age 53,30 ± 12,13 51,55 ± 14,00 0,608**
Gender
  Male
  Female
14 (63,6%)
26 (65,0%)
8 (36,4%)
14 (35,0%)
0.914*
Smoking
No
Yes
31 (66,0%)
9 (60,0%)
16 (34,0%)
6 (40,0%)
0.675*
Dyslipidemia
No
Yes
33 (64,7%)
7 (63,6%)
18 (35,3%)
4 (36,4%)
0,946*
Physical Activity
No
Yes
24 (63,2%)
16 (66,7%)
14 (36,8%)
8 (33,3%)
0,779*
Antihypertensive Therapy
No
Yes
25 (64.1%)
15 (65.2%)
14 (35,.%)
8 ( 34.7%)
0,929*
Body Weight 59,45 ± 12,22 60,59 ± 11,29 0,719**
Body Height 151,43  ± 9,28 150,59 ± 11,61 0,758**
LV Mass index 83,97±16,45 79,79±17,47 0.352**
BMI 23,89 ± 4,82 24,22 ± 5,32 0,444**
Laboratory Finding
HbA1C 5,42 ± 0,37 5,31 ± 0,44 0,281**
UACR ( mg/gram) 12.74±7.64 6.88 ± 6.81 0,004**
Tertile UACR
Tertile 1 (<3,39)
Tertile 2  (3,4 - 7,39)
Tertile 3  (7,4 - 30)
3 (27,3%)
9 (52,9%)
28 (82,4%)
8 (72,7%)
8 (47,1%)
6 (17,6%)
0,002*
* Chi-Square Tests,**one way anova
Table 4 LVDD risk factor multivariate analysis
Variable Coefficient B P value PR CI  95%
UACR Tertile
Tertile 1
Tertile 2
Tertile 3
(Reference)
1,042
2,745
0.219
0.001
2,836
15.57
0.54 - 14.96
2.88 - 84.25
Age 0.014 0.567 1,015 0.96 - 1.06
Gender -0.568 0.448 0.567 0.44 - 7.24
Antihypertensive Therapy -0.040 0.953 0.961 0.25-3.621
 Relationship between demographic characteristic, 
laboratory finding with LVDD is shown in Table 2 
and 3. There is no significant difference between age, 
gender, smoking status, dyslipidemia, physical activity, 
antihypertensive therapy, body mass index, and HbA1C 
between two groups, but there is significant difference 
between UACR tertile in both groups. Prevalence of 
LVDD in tertile 3 is higher than tertile 2 and 1 (82.4%, 
52.9% and 27.3%) with P = 0.002.
Multivariate Analysis
Final results of multivariate logistic analysis that 
searched relationship between LVDD and UACR 
tertile, age, gender and antihypertensive therapy is 
shown in table 4. This research shows upper border 
of normoalbuminuria (tertile 3) is associated with left 
ventricular diastolic dysfunction (odd ratio: 15.57; CI 
95% 2.88 – 84.25). Age, gender and antihypertensive 
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Figure 5.2. Prevalence of LVDD based on Urine Albumine Creatinine Ratio (UACR) 
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therapy are not statistically significant, but in conceptual 
and empirical context, both are confounding factor of 
left ventricular diastolic dysfunction thus it is included 
in multivariate analysis.
Discussion
We found that subject with hypertension with normoal-
buminuria and urine albumin creatinine ratio (UACR) 
range from 7.4 – 30 mg/gram is associated with left 
ventricular diastolic dysfunction. UACR classification 
was adapted from previous study that had been tested 
on coronary disease.21 Most of confounding variable 
can be excluded by-design (by using exclusion criteria) 
and excluded “by-criteria” (by using multivariate 
analysis). This research hypothesis is based on theory 
that Renin Angiotensin Aldosterone System affects 
both kidney and heart. This research is not intended to 
search cut off point of normoalbuminuria for LVDD, 
but to search pathophysiology and association between 
normoalbuminuria with LVDD through RAAS in heart 
and kidney.
 Data in this research shows that upper border of 
normoalbuminuria in high risk population can make 
a higher cardiac risk stratification. It is supported by 
recent studies that focused on association between lower 
albuminuria and cardiovascular risk. Johan, et al, on The 
Framingham Heart Study was using non-hypertensive 
and non-diabetic population for the study found that 
low albuminuria could predict cardiovascular disease 
progress24. Hong, et al, also found that low albuminuria 
was associated with 10 years metabolic syndrome 
prevalence and risk  for coronary disease measured by 
Framingham Risk Score > 20% (high risk) was 22,5 
± 0,7% and 14,5 ± 0,7%, respectively114. Moreover, 
HOPE (Heart Outcomes Prevention Evaluation) found 
that there was no clear threshold for UACR and UACR 
increase that affect cardiovascular risk continuously25. It 
was found that increase of 3.01 mg/gr UACR increased 
major cardiovascular events by 5.9%. It was concluded 
that normal range UACR significantly associated 
with increase myocard dysfunction prevalence. Low 
albuminuria independently associated with left 
ventricular diastolic dysfunction and the cutoff point 
used in this analysis was almost identical with the one 
that was defined in a large cohort study which used for 
cardiovascular death risk 25. 
 It is not clearly known about pathophysiology 
of albuminuria in heart failure patients with normal 
ejection fraction, there are several possible mechanisms. 
One of them is albuminuria associated with many 
inflammatory markers. Systemic inflammation can affect 
coronary microvascular endothel, reduce bioavailability 
of myocardial nitric oxide (NO), which results in lower 
protein kinase G (PKG). Decrease of PKG activity will 
enhance hypertrophy/prohypertrophy process, myocyte 
stiffness, left ventricular diastolic dysfunction and 
ventricular stiffness26. The second possible explanation 
is albuminuria might become an early sign of renal 
damage. Even though renal function is clinically stable, 
decrease of number of nephrons and hyperfiltration, 
and increase of renal proximal tubule saturation can 
result in albuminuria27. There are several compensatory 
mechanisms such as Renin Angiotensin Aldosterone 
System and increase of symphatetic activity, in which 
will affect cardiovascular system. It is supported by 
previous study that has shown an association between 
pulmonary capillary hypertension with renal damage23. 
Thus, low albuminuria represents early renal damage 
and pulmonary capillary hypertension.
 The biggest issue regarding to left ventricular 
diastolic dysfunction algorithm recommendation 
from American Society of Echocardiography and 
European Association of Cardiovascular Imaging (ASE/
EACVI) 2016 is about indeterminate category. In this 
recommendation, indeterminate category is defined 
when there is 50% of positive findings in 4 parameters 
of LVDD. This category is considered in a grey area 
because there is a possibility for someone fall into LVDD 
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without fulfilling more than 50% LVDD positive 
findings. On ASE/EACVI 2016 editorial stated that 
60 – 80% indeterminate subjects had been classified for 
LVDD based on previous guideline, ASE/EACVI 2009. 
Thus, ASE/EACVI 2016 recommendation has a lower 
left ventricular diastolic dysfunction prevalence, but 
its specificity and sensitivity are higher than previous 
guideline. In this research we found 23 subjects fall 
into indeterminate category. Therefore, based on ASE/
EACVI 2009, our LVDD patients might be more than 
62 subjects.
 According on literature, left ventricular mass affects 
parameter for diastolic function and left ventricular 
filling pressure. The larger left ventricular mass will result 
in higher risk for LVDD.28 Compared to Framingham 
Criteria that is not including body surface area (BSA) to 
calculate left ventricular mass, 29 on ASE 2016 criteria 
included BSA on the formula to calculate left ventricular 
mass, therefore this criteria can be used in many 
populations and considered to be more accurate. In our 
research, there is no statistically significant association 
between left ventricular mass with LVDD events. Our 
subjects fall into normal left ventricular mass based on 
ASE 2016 category.
 Gender, age and percentage of antihypertensive 
therapy was analyzed in multivariate analysis. Even it 
is not statistically significant, but in conceptual and 
empirical context these aspects are confounding factor 
of LVDD events and it is supported by many scientific 
data. Woman is considered to have a higher end-systolic 
blood pressure than man (139,7 ± 21,1 vs 123,6 ± 12,6 
mmHg, P = 0,001) and smaller left ventricular chamber 
volume (end-diastolic volume: 96,4 ± 30,6 vs 139 ± 30,7 
ml, P = 0,001). Left ventricular end-systolic elastance 
(2,65 ± 0,10 vs 1,96 ± 0,09 mmHg ml-1, P <0,002) 
and left ventricular diastolic compliance (6.12 ± 0.37 
vs. 10.0 ± 0.50 ml mmHg-1, P <0.001) is found to be 
higher in woman than in man. Therefore it is concluded 
that woman has a higher systolic chamber function 
and lower left ventricular diastolic compliance30. In 
our study, we found no statistic significance between 
gender (dominated by female) and LVDD. One 
possible explanation is body height index that is used 
for calculation of left ventricular mass will decrease 
the effect of gender to LVDD events. Every 100 cm of 
body height approximately increase left ventricular mass 
by 51 grams. In our study population, even though 
dominated by women, their body height is shorter than 
men.
 There is association between aging process and 
cardiovascular diseases, that risk of cardiovascular 
diseases increases with age. Cardiovascular disease is 
the leading cause of death for people at age 65 years 
old and above (40%) and 80% of cardiovascular death 
occurred in this group.31 For normal population and 
asymptomatic patients, declining diastolic function 
represents with comparison E/e’ > 15, seldom is found 
on people below 65 years old. In people  ≥ 65 years 
old, it is 14% at group age 65 – 74 years old and 24% 
at group age > 74 years old.32 A cross-sectional study 
done by Zanchetti, et al, (APROS diadys study) found 
that from 2425 elderly patients (≥ 65 years old), the 
prevalence of LVDD was 25.8% (649 patients). This 
diastolic dysfunction prevalence is increasing along with 
increasing age, with minimal value of 22.7% (65 – 70 
years old) and maximal value of 41.2% (> 80 years old) 
33. Our population study has average age of 52 years old. 
 Sabine, et al34, found that long term weight loss on 
obesity people is associated with left ventricular diastolic 
improvement. Our study found that body mass index 
and physical activity were not significantly related 
to LVDD event. This might be explained by absence 
of previous BMI history recorded, and we could not 
conclude that the normal BMI at our sampling time was 
due to physical activity and/or exercise with a higher 
BMI previously. We also found no significant association 
between smoking and dyslipidemia with LVDD. This 
might be due to our samples were dominantly not 
smoking and not having dyslipidemia.
 Antihypertensive therapy that altering RAAS such 
as angiotensin converting enzyme inhibitor (ACE 
inhibitor) can affect to LVDD event.35 Reduced 
preload that induced by ACE inhibitor will affect 
both ventricular dimension, left ventricular geometry 
and both ventricular filling. Reduced right ventricular 
dimension is associated with left ventricular geometry 
adaptation and reduced left ventricular diastolic 
pressure, which facilitates left ventricular filling and 
pulmonary vein drainage.35 Most of our samples had 
no antihypertensive therapy (61.3%). From twenty four 
subjects (38.7%) with antihypertensive therapy, four 
subjects had ACE inhibitor, one subject had calcium 
channel blocker and nineteen subjects had not known 
the name of antihypertensive drug. Small number of 
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subjects with antihypertensive therapy made association 
between antihypertensive therapy and LVDD events in 
our study was not statistically significant.
Limitation of the Study
First of all, this study was not intended to prove a 
causal relationship because independent and dependent 
variable sampling was done in one time thus we had no 
clear temporal relationship between these variables and 
could not conclude which one which was the cause and 
the effect. Second, this research was not representing 
progression of the disease, its incidence and prognosis. 
Third, there might be prevalence or incidence bias due 
to possibility of misinterpretation of risk factor effects 
over a time period as an effect of the disease. Fourth, 
even though electrocardiography (ECG) was used in our 
study, but it was not enough to exclude chronic or stable 
coronary disease. We could not use Framingham score to 
estimate cardiovascular risk in our population because we 
did not include one of Framingham 2008 variable score. 
Moreover, regional wall motion abnormality (RMWA) 
of myocard with echocardiography also can’t be used 
for exclusion because our population had intermediate 
pretest probability. Therefore, echocardiography stress 
test would be more sensitive to diagnose stable coronary 
disease.36
 Our population was dominated by woman, age 
52 years old (average), not smoking, no obesity, no 
diabetes mellitus and no left ventricular hypertrophy, 
which fall into moderate risk for cardiovascular disease 
according to Framingham 1991. Fifth, confounding 
factor such as anemia could not be excluded. Nagueh, 
et al23 stated echocardiography that affected by blood 
volume  is Doppler mitral inflow method, while our 
study diagnosed LVDD by using Tissue Doppler 
Imaging (TDI) due to normal ejection fraction 
according to recent ASE guideline for LVDD criteria. 
Therefore, it might not be affected with low hemoglobin 
concentration (loading condition). Other confounding 
factor such as systemic inflammation (e.g. sarcoidosis, 
urinary tract infection) could not be excluded. These 
disease proportion in general population were very 
small: 0.1%37 and 0.7%38 respectively, thus it might 
me assumed its effect on our study would be very low. 
On urinary tract infection (UTI) patients, proteinuria 
might not be found, but if there is existed, it will be a 
macroalbuminuria. Even though UTI often associated 
with proteinuria, its relationship is not clearly known. 
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